Download BioRexis Appoints Vanaja V. Ragavan, MD, Vice President, Clinical

BioRexis Appoints Vanaja V. Ragavan, MD, Vice President, Clinical and
Regulatory Affairs
King of Prussia PA, April 13, 2004 – BioRexisTM Pharmaceutical Corporation
announced today the appointment of Vanaja Ragavan, M.D., to the position of vice
president, clinical and regulatory affairs. Dr. Ragavan joins BioRexis from Novartis
Pharmaceuticals, where she was the global head of women’s health/urology, clinical
research and development. At Novartis, she was responsible for clinical development
and marketing support of several product lines, such as hormone therapies, urology
products and calcitonin, and for managing the strategic growth of the women’s health
business.
Dr. Ragavan has more than 15 years of experience in clinical and strategic development
at various pharmaceutical companies including RPR/Aventis, Wyeth-Ayerst and Novo
Nordisk. She also served for four years at the U.S. Food and Drug Administration. Dr.
Ragavan is a board certified endocrinologist who received her medical degree from New
York University School of Medicine and undergraduate degree in biology from Harvard
University.
BioRexis’ CEO, David R. King, said “We are delighted to welcome Vanaja to our
management team. She brings to BioRexis many years of clinical and regulatory
experience that complements the strong backgrounds and successful track records of our
other senior managers in development and commercialization of protein therapeutics.
Her unique insights and expertise will enable us to continue our rapid progress in drug
development as we position our company for future success. With our recent $30 million
financing, BioRexis is poised for tremendous growth, and also expects to be adding a
CFO and a senior business development executive later this year.”
About BioRexis Pharmaceutical Corporation
BioRexis is a privately-held biopharmaceutical company that develops novel, extended
half-life protein and peptide drugs with superior pharmacology and Trans-bodiesTM to
replace conventional monoclonal antibodies. BioRexis’ technology involves the fusion
of peptides and proteins to a modified version of the blood serum protein transferrin,
thereby prolonging their circulatory half-life, improving efficacy, decreasing side effects
and reducing dosage. The company’s lead product is a peptide fusion currently in
preclinical trials for type 2 diabetes. Additional biopharmaceutical products under
development include a novel longer-acting interferon and an erythropoietin receptor
agonist. For additional information, please visit http://www.biorexis.com/.
For Information Contact:
David R. King
Chief Executive Officer
BioRexis Pharmaceutical Corporation
(610) 313-4001
[email protected]